| |
|
|
 |
July 16, 2010
Biolux Research Announces
Financing For Continued Development of its Light Accelerated
Orthodontics Product
VANCOUVER, B.C., CANADA - July 16, 2010 - Biolux Research Ltd. is pleased to announce that it has recently raised over CAD $1MM as part of a new equity offering of common shares. The funds were raised through a convertible debt mechanism offered to existing shareholders and optionholders of the company in advance of a planned further offering to the broader investment community in the near future.
|
 |
June 24, 2010
Biolux Research Announces
Filing of Patent Application for Regulation of Orthodontic
Tooth Movement
VANCOUVER, B.C., CANADA - June 24, 2010 - Biolux
Research Ltd. is pleased to announce the filing of a second
patent application for a method and apparatus for accelerating
and regulating orthodontic tooth movement with light treatment
technology. The company filed the application through
the Patent Cooperation Treaty process, which will allow
for expansion of patent protection to over 200 countries,
including all major markets of the world.
|
|
June 10, 2010
Biolux Research Announces
Presentation of Accelerated Orthodontic Study Results
at International Association for Dental Research General
Session 2010
VANCOUVER, B.C., CANADA - June 10, 2010 - Biolux
Research Ltd. is pleased to announce that important results
from our accelerated orthodontics research program will
be presented at the upcoming International Association
for Dental Research (IADR) General Session in Barcelona,
Spain, July 14-17, 2010. The IADR is the pre-eminent research
organization in the world of dentistry, with a mission
to advance research and increase knowledge for the improvement
of oral health worldwide, to support and represent the
oral health research community, and to facilitate the
communication and application of research findings. This
year’s meeting will be highly attended by more than
5000 members from all corners of the globe.
|
|
May 10, 2010
Biolux Research announces Presentation of
the Osseopulse™ at Ontario Dental Association
Annual Spring Meeting 2010
VANCOUVER, B.C., CANADA - May 10, 2010 - Biolux Research Ltd. is pleased to announce that the OsseoPulse? Bone Regeneration System has been selected for presentation in the New Products Forum at the Ontario Dental Association Annual Spring Meeting in Toronto May 13-15, 2010. The presentation will highlight the clinical treatment opportunities with the OsseoPulse™, an innovative light treatment product that stimulates bone regeneration, allowing the dentist to dramatically reduce time to load dental implants and to treat challenging cases with increased confidence. The forum is a classroom setting with interactive discussion, and the presentation is supported by Citagenix Inc, distributor of the OsseoPulse™ in Canada.
|
|
April 26, 2010
Biolux Research announces Design Award
for the Osseopulse™ Bone Regeneration
System for Implantology
VANCOUVER, B.C., CANADA - April 26, 2010 - Biolux Research Ltd. is pleased to announce that it has
received the prestigious red dot product design award for the OsseoPulse™ Bone Regeneration System, in
recognition of the innovative design of the medical product.
|
|
November 5, 2009
Biolux Research announces financing and investigational testing authorization for the development of a light accelerated orthodontics product
VANCOUVER, B.C., CANADA - November 5, 2009 - Biolux Research Ltd. is pleased to announce that it has issued $860,000 in new shares as part of a new equity offering of common shares.
The offering included a debt conversion vehicle to convert shareholder loans, in which the principle shareholders of the company converted the majority of promissory notes into new shares. The majority of the offering was purchased by Elac Venture Corporation, a private equity investing firm based in Hong Kong. The remainder of the offering was purchased by existing shareholders and individual investors.
|
|
August 13, 2009
Biolux Research announces
support from the National Research Council of Canada Industrial
Research Assistance Program for the development of light
accelerated orthodontics product.
VANCOUVER, B.C., CANADA - Aug. 13, 2009 - Biolux
Research Ltd. is pleased to announce that it has received
a non-repayable financial contribution from the National
Research Council of Canada Industrial Research Assistance
Program (NRC-IRAP) to help accelerate the development
and commercialization of a new light treatment device
for orthodontics. The new product will be designed to
significantly accelerate tooth movement during orthodontic
treatment, and thus radically reduce treatment times and
improve the experience for patients.
NRC-IRAP will contribute approximately CAD $205,000 over
the next 18 months to support the research and prototyping
of the device, to clinically test and validate the effectiveness
of the technology, and to develop a high quality, manufacturable
product. In addition to the contribution, NRC-IRAP will
provide both technical and business oriented advisory
services.
|
|
June 26, 2009
Biolux
Research Announces OsseoPulse™ Production Milestone
and Expanding Distribution.
VANCOUVER, B.C., CANADA - Jun. 26, 2009 - Biolux
Research Ltd. is pleased to announce today that we have
achieved a production milestone for our OsseoPulse™
Bone Regeneration System, and have expanded our product
distribution into additional markets.
Since launching the OsseoPulse™ in Canada in Oct.
2008, we have received regulatory clearance in Canada,
Korea, Israel, and Europe. Achieving CE Mark is a significant
achievement as it provides direct regulatory approval
for approximately 20 European countries.
|
|
June 15, 2009
Biolux
Research Announces Filing of Patent Application for Light
Accelerated Orthodontics.
VANCOUVER, B.C., CANADA - Jun. 15, 2009 - Biolux
Research Ltd. is pleased to announce today the filing
of a patent application for a method and apparatus for
accelerating orthodontics with light treatment technology.
Orthodontics is the dentistry specialty of moving teeth
within the jaw to provide better alignment and other benefits,
and is a very common dental procedure. There are approximately
10,000 orthodontists in the US and Canada, with approximately
2 million patients undergoing orthodontic treatment in
an average year. Orthodontic treatment is traditionally
achieved with appliances (braces) that provide physical
force to the teeth and move the roots through the bone.
Typical orthodontic treatments range from 12 to 36 months,
due to the natural limitations of bone resorption and
regeneration processes, and consist of frequent visits
to the orthodontist for adjustments and tightening. Reducing
overall treatment time can provide a much better experience
for the patient, including less social stigma, discomfort,
and change of diet, while accelerating the process presents
new opportunities to the orthodontist to provide different
and better care.
|
|
March 18, 2009
Biolux
Research Announces European Launch of the OsseoPulse?
Bone Regeneration System.
VANCOUVER, B.C., CANADA - Mar. 18, 2009 - Biolux
Research Ltd. is pleased to announce today that it will
be launching the OsseoPulse? Bone Regeneration System
at the 33rd International Dental Show from Mar. 24 - 29.
http://english.ids-cologne.de/
IDS 2009 in Cologne, Germany is the world's leading trade
show and sector meeting place for decision-makers from
dental practices, dental labs, the specialist dental trade,
the dental industry and from research and development.
More than 100,000 visitors gather information on new products
and innovations from some 1,750 exhibitors from 55 countries.
Launch of the OsseoPulse™ in Europe builds on recent
milestones of achieving both ISO 13485 certification and
CE Mark regulatory approval for the product. The CE Mark
allows Biolux to market the device directly to the 27
countries within the European Union plus the additional
4 countries that recognize the CE Mark. The dental implant
market in Europe represents approximately 40% of the worldwide
implant market, and is thus a significant market for Biolux
and the OsseoPulse™.
|
|
February 5, 2009
Biolux Research Announces
ISO 13485 Quality System Certification and CE Mark Regulatory
Approval of the OsseoPulse? Bone Regeneration System.
VANCOUVER, B.C., CANADA - Feb. 5, 2009 - Biolux
Research Ltd. is pleased to announce today two news items
that will further enhance the commercialization of its
OsseoPulse? Bone Regeneration System.
The company has successfully completed its ISO 13485 certification
audit and has been awarded a final certificate. ISO 13485
is a worldwide-recognized medical device quality system
standard, and certification to this standard is a requirement
for any medical device company to develop, manufacture,
and market products in Europe, Canada, and other markets.
The Biolux quality system was audited by BSI Management
Systems America Inc., one of the foremost auditing bodies
in the world.
|
|
December 1, 2008
Biolux Research Announces
Commercial Launch of the OsseoPulse? Bone Regeneration
System in Korea.
VANCOUVER, B.C., CANADA – Dec. 1, 2008
– Biolux Research Ltd. is pleased to announce today
that it has launched the OsseoPulse? Bone Regeneration
System in South Korea. The product is now available for
sale exclusively through DIO Implant Inc., a division
of publicly-traded Dong Seo Inc, under the distribution
agreement signed earlier in 2008. The product has been
approved by the Korean FDA as a Class II device, and product
has been shipped to DIO to begin marketing and sales of
the OsseoPulse? to luminaries and opinion leaders.
|
|
October 31, 2008
Biolux Research Announces
Launch of the OsseoPulse™ Bone Regeneration System
in Canada.
VANCOUVER, B.C., CANADA – Oct. 31, 2008
– Biolux Research Ltd. is pleased to announce today
that it has launched the OsseoPulse? Bone Regeneration
System in Canada. The product is now available for sale
through Citagenix Inc., our exclusive distribution partner.
The product has been approved by Health Canada as a class
II medical device, and received a medical device license
earlier in 2008. Production quality has been proven, sales
training has taken place, and product has been shipped
to Citagenix to begin marketing and sales.
|
|
August 20, 2008
Biolux Research Announces
Appointment of Dr. Cameron Clokie as Chair of Scientific
Advisory Board.
VANCOUVER, B.C., CANADA ? August 20,
2008 ? Biolux Research Ltd. Is very pleased to announce
that it has appointed Dr. Cameron Clokie, DDS, OMFS, PhD,
as Chair of its Scientific Advisory Board (SAB). Dr. Clokie
is renowned in the field of implantology, and was part
of the pioneering group to develop the clinical field
in Canada decades ago. For the past ten years Dr. Clokie
served as Head of Oral and Maxillofacial Surgery, Faculty
of Dentistry, University of Toronto, and is currently
a partner at very successful private practice in Toronto.
Dr. Clokie has also successfully commercialized numerous
dental products in the tissue regeneration space.
|
|
July 24, 2008
Biolux
Research Announces Agreement with Citagenix for Exclusive
Distribution of the OsseoPulse? Bone Regeneration System
in Canada.
VANCOUVER, B.C., CANADA ? July 24, 2008
? Biolux Research Ltd. announced today that it has signed
a new distribution agreement with Citagenix Inc. to commercialize
the OsseoPulse? Bone Regeneration System in Canada. The
agreement provides exclusivity and a long term commitment
necessary to introduce the new product to the Canadian
dental market.
|
|
May 7, 2008
Biolux
Research Announces Health Canada Regulatory Approval for
its OsseoPulse™
Bone Regeneration System.
VANCOUVER, B.C., CANADA - May 7, 2008
– Biolux Research Ltd. announced today that it has
received approval from Health Canada to market the OsseoPulse™
Bone Regeneration System in Canada. The OsseoPulse™
is classified by Health Canada as a Class II medical device,
and received a Medical Device Licence for the system and
its components. The licence was applied for in partnership
with StarFish Medical of Victoria, BC.
|
|
April 4, 2008
Biolux
Research Announces Appointment of President and CEO for
Commercialization
of its OsseoPulse™ Bone Regeneration System.
VANCOUVER, B.C., CANADA. - April
4, 2008 – Biolux
Research Ltd. announced today that it has appointed medical
device industry veteran Kevin Strange as President and
CEO. Mr. Strange’s primary responsibilities will
be to lead the commercialization of the unique OsseoPulse™
Bone Regeneration System for dentistry, including product
launch into Canada, the US, and Europe, as well as executing
work in Korea with our strategic partner DIO Implant,
subsidiary of a publicly listed medical device manufacturer
and distributor. Dr. Peter Brawn, Chairman and Founder
of Biolux, will continue the key roles of clinical and
scientific visionary and early product research and development.
|
| |
|
September 22, 2007
Biolux Research Announces
Memorandum of Understanding with Dong Seo Inc. of South
Korea
for its OsseoPulse™ Bone Regeneration System.
VANCOUVER, B.C., CANADA. - September
18, 2007 – Biolux
Research Ltd. announced today that it has signed a Memorandum
of Understanding (MOU) with DIO Implant, a wholly owned
subsidiary of Dong Seo Inc, which in turn is a KOSDAQ
stock exchange listed company and one of Korea’s
leading dental implant manufacturers. The MOU is for the
purpose of product evaluation, marketing and completion
of an exclusive distribution agreement for the OsseoPulse™
dental bone regeneration system in South Korea.
|
|
|
Biolux Research Ltd.